Harnessing the Prix Galien to Highlight the Nordics+ Community of Innovators

Through the new “Bridges” initiative, Prix Galien will leverage its convening power to build and strengthen relationships that showcase the Nordic1 region’s long history of creative, integrated approaches to maximizing its reach and market potential in the larger regional/global biopharmaceutical and adjacent technology sectors.

PRIZE CATEGORIES
Best Pharmaceutical Agent
Best Biotechnology Product
Best Medical Technology (Diagnostic & Digital)
Best AI Advances in Human Health
Best Public Sector Innovation
Best Product for Rare/Orphan Diseases

An illustrious committee of industry leaders
Judges of the Prix Galien Bridges Awards are among the industry’s brightest luminaries from their respective countries. Respected globally, we are particularly excited to bring them together for the Prix Galien Bridges Awards where we anticipate particularly meaningful exchange through the prism of the geographical bridge they represent.

Maria Alonso_Web
Editor-in-Chief, Drug Delivery and Translational Research Journal, CIMUS Research Institute
María José ALONSO, MD, PhD
Alon Chen_web
President, Weizmann Institute of Science
Alon CHEN, PhD
Mikael Dolsten_Web
Former Chief Scientific Officer & President, Worldwide R&D and Medical, Pfizer, Inc. (Chair)
Mikael DOLSTEN, MD, PhD
Emma Guttman_Web
Chair, Kimberly & Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai
Emma GUTTMAN-YASSKY, MD, PhD
Mirza Mansoor_Web
Medical Director, Nordic Society of Gynaecologic Oncology-Clinical Trial Unit
Mansoor MIRZA, MD
Aarno Palotie_web
Research Director of Human Genomics, Institute for Molecular Medicine Finland
Aarno PALOTIE, MD, PhD
Erik Renstrom_Web
Vice Chancellor, Lund University
Erik RENSTRÖM, PhD
John Arne Rottingen_Web
CEO, Wellcome
John-Arne RØTTINGEN, MD, PhD
Veronika Sexl_Web
Rector, University of Innsbruck
Veronika SEXL, MD, PhD
Kári Stefánsson_Web
CEO, deCODE genetics
Kári STEFANSSON, MD, PhD

Through a set of prestigious annual awards, unique, internal stakeholder dialogue, public events, and persuasive published research and communications, we will help make the case for innovative biopharma science as a driver of balanced development and for the transformative knowledge and business practices that add to quality of life for patients and more efficient use of scarce health resources. We recognize the importance of leveraging these strengths to enhance the science base in selected small and middle-sized markets that have yet to secure their potential in attracting the scalable investments necessary to bring new cures and treatments to a wider circle of patients.

IPG

Prix Galien International 2024

We deliberately use the term “Bridges” given our aim to – through this initiative - facilitate expertise and knowledge transfers around the Nordic region’s innovation precedents and best practices with five additional strategic countries (comprising the plus in Nordics+): Austria, Israel, The Netherlands, Portugal, and Spain. Countries in the region with existing, active Prix Galien programs – Belgium, France, Germany, Greece, and Italy – have pledged their collaboration and solidarity.

Participating_Countries-1

1 The Nordic countries are a geographical and cultural region in Northern Europe and the North Atlantic. It includes the sovereign states of Denmark, Finland, Iceland, Norway and Sweden; the autonomous territories of the Faroe Islands and Greenland; and the autonomous region of Åland.

Group 1035
Prix Galien Bridges Charter
Group 1037
Worldwide Committees
Group 1033
FAQ
Contact Us
PRIX GALIEN HALL OF FAME
Search the innovations that have made the greatest impact on human health over the course of the past 50 years worldwide.